

Haematologica  
HAEMATOL/2015/124651  
Version 4

Four genes predict high risk of progression from smoldering to  
symptomatic multiple myeloma (SWOG S0120)

Disclosures: B.B. is a co-inventor on patents and patent applications related to use of GEP in cancer medicine that have been licensed to Myeloma Health, LLC. Other authors have no conflicts to declare.

Contributions: R.K wrote the manuscript and assisted with the analyses; A.R and A.H performed statistical analyses and assisted with the manuscript; C.H, X.P, F.V.R, M.Z, Y.J, J.E, S.Y provided feedback and assisted with the analyses; N.P and C.B provided data support; P.Q and J.C provided statistical support; G.M and M.D guided and assisted with the research and manuscript; B.B formulated, designed the research and assisted with the manuscript.